Rockwell Automation vs Tempus AI — how do they compare? Rockwell Automation trades at $436.4 (market cap $48.21B), while Tempus AI trades at $70.18 (market cap $12.58B). The key difference: Rockwell Automation is far larger — about 3.8× Tempus AI's market cap, and Rockwell Automation pays a 1.27% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rockwell Automation for 74 Days and Tempus AI for 22 Days on average.
| ROK | TEM | |
|---|---|---|
Market Cap | $48.21B | $12.58B |
Volume | 953,342 | 7,444,569 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $495.08 | $99.28 |
52-Week Low | $333.75 | $41.55 |
Typical Hold Time | 74 Days | 22 Days |
Enterprise Value | $51.34B | $13.21B |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $441.9, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $489.89 implying 11% upside. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending, and maintains strong profitability with a 13.38% net income margin and 34.47% ROE. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms.
ROK presents a growth opportunity driven by automation demand and digital transformation trends, but faces risks from high valuation multiples (P/E 41.38) and cyclical industrial spending. Analyst sentiment is mixed with 68% hold ratings, reflecting caution amid solid fundamentals. Investors should weigh earnings consistency against premium pricing.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →